此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (RASolute 305)

2026年11月5日 更新者:Revolution Medicines, Inc.

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

研究概览

详细说明

This is a Phase 3, global, randomized, double-blind study designed to evaluate whether treatment with zoldonrasib in combination with Investigator choice of chemotherapy will improve progression-free survival or overall survival compared to placebo in combination with Investigator choice of chemotherapy when given to patients with previously untreated, 1L metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Choice of chemotherapy (mFFX or GnP) will be at the discretion of the Investigator.

Patients will be randomized to one of two arms: zoldonrasib + Investigator choice of chemotherapy (Arm A) or placebo + Investigator choice of chemotherapy (Arm B).

研究类型

介入性

注册 (估计的)

670

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Revolution Medicines Study Director
  • 电话号码:1-844-2-REVMED
  • 邮箱:medinfo@revmed.com

学习地点

      • Salzburg、奥地利、05020
        • 招聘中
        • Universitatsklinikum der PMU Salzburg Landeskrankenhaus
      • Florence、意大利、50134
        • 招聘中
        • Azienda Ospedaliera Universitaria Careggi
      • Padova、意大利、35128
        • 招聘中
        • Instituto Oncologico Veneto - IRCCS
    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • Mayo Clinic Arizona
        • 接触:
          • Bekaii-Saab
          • 电话号码:855-776-0015
      • Tucson、Arizona、美国、85719
        • 招聘中
        • The University of Arizona Cancer Center-North Campus
        • 接触:
    • Connecticut
      • New Haven、Connecticut、美国、06511
    • Florida
      • Gainesville、Florida、美国、32610
      • Jacksonville、Florida、美国、32224
        • 招聘中
        • Mayo Clinic Florida
        • 接触:
          • Babiker
          • 电话号码:855-776-0015
      • Tampa、Florida、美国、33612
    • Georgia
    • Illinois
      • Chicago、Illinois、美国、60637
        • 招聘中
        • University of Chicago Medical Center
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21287
    • Massachusetts
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic Rochester
        • 接触:
          • Jazieh
          • 电话号码:855-776-0015
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
      • New Brunswick、New Jersey、美国、08901
    • New York
    • North Carolina
      • Durham、North Carolina、美国、27710
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Vanderbilt-Ingram Cancer Center
        • 接触:
    • Texas
      • Houston、Texas、美国、77030
      • London、英国、SW3 6JJ
        • 招聘中
        • Royal Marsden Hospital
      • London、英国、EC1A 7BE
        • 招聘中
        • St Bartholomew's Hospital - Barts Health NHS Trust
      • London、英国、W12 0HS
        • 招聘中
        • Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital
      • Nijmegen、荷兰、6525
        • 招聘中
        • Radboud UMC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed pancreatic adenocarcinoma.
  • Diagnosis of metastatic disease ≤ 6 weeks prior to screening.
  • Documented KRAS G12D mutation status.
  • Measurable disease per RECIST v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • Able to take oral medications.

Exclusion Criteria:

  • Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.
  • Prior systemic RAS-targeted therapy any time prior to randomization.
  • Presence of other known driver mutations with approved targeted therapies
  • Active or known history of untreated central nervous system metastatic disease.
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 28 days prior to randomization.
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: zoldonrasib + chemotherapy

study drug in combination with Investigator choice chemotherapy (mFFX or GnP)

IV infusion

oral tablets

IV infusion

IV infusion

IV infusion

IV infusion

IV infusion

安慰剂比较:Arm B: placebo + chemotherapy

placebo in combination with Investigator choice chemotherapy (mFFX or GnP)

IV infusion

IV infusion

IV infusion

IV infusion

IV infusion

IV infusion

oral tablets

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression free survival (PFS)
大体时间:Up to approximately 4 years

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed per response evaluation criteria in solid tumors (RECIST) v1.1 by Investigator.

Up to approximately 4 years
Overall survival (OS)
大体时间:Up to approximately 4 years

OS is defined as the time from randomization until death from any cause.

Up to approximately 4 years

次要结果测量

结果测量
措施说明
大体时间
PFS per blinded independent central review (BICR)
大体时间:Up to approximately 4 years

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed RECIST v1.1 by BICR.

Up to approximately 4 years
Objective response rate (ORR)
大体时间:Up to approximately 4 years

Objective response is defined as partial response (PR) or complete response (CR) as assessed per RECIST v1.1 by Investigator and BICR.

Up to approximately 4 years
Duration of response (DOR)
大体时间:Up to approximately 4 years

DOR is defined as time from first evidence of objective response (PR or CR) to disease progression or death due to any cause, whichever occurs first, as assessed by the investigator and BICR.

Up to approximately 4 years
Incidence of adverse events (AEs)
大体时间:Up to approximately 4 years

Percentage of patients with AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5

Up to approximately 4 years
Changes in vital signs
大体时间:Up to approximately 4 years

Number of patients with clinically significant changes in vital signs.

Up to approximately 4 years
Changes in clinical laboratory test values
大体时间:Up to approximately 4 years

Number of patients with changes from baseline in clinical laboratory test values

Up to approximately 4 years
Health-related outcome assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) pain scale
大体时间:Up to approximately 4 years

EORTC QLQ-PAN26 consists of 26 questions relating to disease symptoms, treatment side effects and emotional issues specific to pancreatic cancer. The pancreatic pain subscale assesses abdominal pain, back pain, and pain while lying down. Change in score from baseline in the pain subscale will be assessed with higher scores on the pain subscale indicating more severe pain and worsening function.

Up to approximately 4 years
Quality of life as assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status score
大体时间:Up to approximately 4 years

EORTC QLQ-C30 consists of 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties), and an overall scale for global health status. It uses a mix of 4-point scales and 7-point scales. Change from baseline in EORTC QLQ-C30 global health status will be assessed. Higher scores on functional scales reflect better functioning, whereas higher scores on symptom scales reflect higher symptom burden.

Up to approximately 4 years
Concentration of zoldonrasib in Arm A
大体时间:Up to Cycle 5 Day 1 (each cycle is 28 days)

Pre-dose trough and post-dose blood concentrations of zoldonrasib at selected visits.

Up to Cycle 5 Day 1 (each cycle is 28 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月22日

初级完成 (估计的)

2028年12月30日

研究完成 (估计的)

2030年4月22日

研究注册日期

首次提交

2026年5月26日

首先提交符合 QC 标准的

2026年5月26日

首次发布 (实际的)

2026年6月2日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅